---
layout: default
title: Caffeine Citrate
parent: 僅模型預測 (L5)
nav_order: 18
evidence_level: L5
indication_count: 0
---

# Caffeine Citrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# CAFFEINE CITRATE: Drug Repurposing Evaluation — TxGNN Predictions Not Available

## One-Sentence Summary

Caffeine Citrate is a xanthine derivative formulation, with no original indication data recorded in this evidence pack.
The TxGNN model has **not generated any predicted indications** for this candidate — the evidence pack contains critical data gaps that prevent a complete repurposing evaluation.
At present, **no clinical trial or literature evidence** can be linked to a repurposing target.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions generated |
| Norway Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction is Available

The TxGNN pipeline returned an empty `predicted_indications` array for Caffeine Citrate. Three likely causes explain this outcome:

**Missing graph identity.** The DrugBank ID is not recorded in the evidence pack. Caffeine Citrate is a salt/citric acid co-formulation of caffeine (DrugBank: DB00201), and without a resolved node identity, the knowledge graph cannot correctly anchor this compound for link prediction.

**Absent mechanism of action data.** MOA data is marked as a high-severity data gap. Without pharmacological feature vectors, the TxGNN model cannot identify mechanistic similarity to disease nodes, which is central to its prediction logic.

**Possible entity mismatch.** The pipeline may have attempted to match "CAFFEINE CITRATE" as a distinct entity rather than mapping it to the parent caffeine node. A re-run with the correct DrugBank ID and entity mapping is needed before any prediction can be interpreted.

---

## Norway Market Information

No authorizations are on record. Caffeine Citrate is not marketed in Norway under this name at the time of data collection (2026-04-20).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack produces no TxGNN predicted indications, records no original indications, and contains blocking-level safety data gaps — a repurposing evaluation cannot be meaningfully completed until the issues below are resolved.

**To proceed, the following is needed:**

- **Resolve DrugBank ID**: Confirm mapping to DB00201 (caffeine) or identify a distinct Caffeine Citrate entry; update the pipeline's drug node accordingly
- **Re-run TxGNN pipeline**: Execute with the corrected drug node to generate `predicted_indications`
- **Retrieve MOA data**: Query DrugBank API for mechanism of action (xanthine / adenosine receptor antagonism / phosphodiesterase inhibition)
- **Retrieve safety data**: Download and parse the package insert PDF from the relevant regulatory authority to populate warnings and contraindications
- **Confirm original approved indication(s)**: Caffeine Citrate is clinically established for **apnea of prematurity** in neonates — this should be recorded as the reference indication before repurposing analysis proceeds
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

